Sanjay Singh

11PUBLICATIONS
10CO-AUTHORS
Regenerative medicine (incl. stem cells)Medical bacteriologyMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Biological adaptation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 10, 2026
Novel regimens for treatment of Mycobacterium avium lung disease based on advanced in vitro systems and the mathematics of basis functions.

Shashikant Srivastava, Sanjay Singh, Gunavanthi D Boorgula

|Apr 09, 2026
Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease.

Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula

|Dec 10, 2025
Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease.

Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula

|Sep 22, 2025
Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis.

Sanjay Singh, Megan Devine, Tawanda Gumbo

|Sep 10, 2025
Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus.

Avneesh Shrivastava, Gunavanthi D Boorgula, Sanjay Singh

|Aug 13, 2025
Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for Mycobacterium abscessus Lung Disease.

Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula

Pageof 2